Pfizer is moving its business focus away from COVID-19 products to its broader non-COVID portfolio, which grew 5% in Q2 2026. The company beat earnings estimates by 12% and raised its revenue guidance by $500 million, signaling strong financial health. Insider buying, including $1 million by CEO Albert Bourla and nearly $2 million by other directors, shows leadership confidence in Pfizer's future. Pfizer is also cutting costs and advancing new drug developments, aiming for sustainable growth beyond the pandemic.
Revolution Medicines closed at $205.55 on August 11, 2026, reaching a $44.1 billion market cap driven by its promising RAS-targeting oncology pipeline. The company has no current product revenue but shows strong clinical results, especially with dara...
Investors seeking reliable income and growth should consider five S&P 500 stocks with dividend yields above 6%, including Altria, Pfizer, VICI Properties, General Mills, and Verizon. These companies have long histories, stable dividends, and strong m...
Pfizer's Q2 2026 results revealed 1% operational revenue growth and a 12% earnings per share beat, driven by strong non-COVID sales and a robust product pipeline. The company's Cost Realignment Program is expected to save $7.2 billion by 2026 and an ...
